Patents Examined by Po-Chih Chen
  • Patent number: 11453639
    Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, G1, G2, and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: September 27, 2022
    Assignee: ACUITAS THERAPEUTICS, INC.
    Inventor: Xinyao Du
  • Patent number: 11446280
    Abstract: Provided herein are compounds, derivatives thereof, and compositions including one or more of the compounds and derivatives, and methods for prevention and/or treatment of microbial infections and/or related diseases or conditions. The present compounds and/or derivatives thereof can be represented by Formula (I): The present methods include administering to a subject an effective amount of one or more compounds of Formula (I). In one embodiment, the microbial infections are bacterial infections. More specifically, the bacterial infections are staphylococcal infections.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: September 20, 2022
    Assignee: VERSITECH LIMITED
    Inventors: Yi Tsun Richard Kao, Peng Gao, Xuechen Li, Ming Liu
  • Patent number: 11447461
    Abstract: This invention is benzothiophene-based estrogen receptor downregulators and their compositions and uses to treat estrogen-related medical disorders.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: September 20, 2022
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Gregory R. Thatcher, Rui Xiong, Jiong Zhao, Debra A. Tonetti
  • Patent number: 11427548
    Abstract: The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: August 30, 2022
    Assignee: ARVINAS OPERATIONS, INC.
    Inventors: Andrew P. Crew, Hanqing Dong, Jing Wang, Xin Chen, Yimin Qian, Kurt Zimmermann, Michael Berlin, Lawrence Snyder
  • Patent number: 11420935
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating deseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: August 23, 2022
    Assignee: VIVACE THERAPEUTICS, INC.
    Inventors: Andrei W. Konradi, Tracy Tzu-Ling Tang Lin
  • Patent number: 11407728
    Abstract: The present disclosure provides chemical compound derivatives of a class of biological lipid mediators known as endocannabinoids and methods of synthesizing the compositions. These compounds are useful for treating cancer, reducing inflammation, reducing platelet aggregation, and reducing angiogenesis.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: August 9, 2022
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Aditi Das, Josephine E. Watson
  • Patent number: 11407713
    Abstract: An isothiocyanate functional surfactant, wherein the protonated form of the surfactant includes the structure of formula (IA): wherein R1 includes the structure of formula (IIA), (IIIA), or (IVA), wherein X includes an integer ranging from approximately 0 to approximately 20, wherein R2 comprises a linear or branched aliphatic group containing approximately 8 to approximately 25 carbon atoms, and wherein R3 comprises an aliphatic or aromatic group containing approximately 1 to approximately 20 carbon atoms and at least one —N?C?S group.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: August 9, 2022
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 11384049
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating deseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: July 12, 2022
    Assignee: VIVACE THERAPEUTICS, INC.
    Inventors: Andrei W. Konradi, Tracy Tzu-Ling Tang Lin
  • Patent number: 11377433
    Abstract: The present invention makes it possible to provide a method for producing a polyfunctional sulfur-containing epoxy compound, the method being characterized in that a polyfunctional thiol is reacted with an epihalohydrin in the presence of a reducing agent to form a polyfunctional sulfur-containing halohydrin, which is then reacted with a basic compound. The reducing agent is preferably at least one selected from the group consisting of sodium borohydride, lithium borohydride, lithium aluminum hydride, diisobutylaluminum hydride, and hydrazine.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: July 5, 2022
    Assignee: MITSUBISHI GAS CHEMICAL COMPANY, INC.
    Inventors: Yousuke Imagawa, Hiroshi Horikoshi
  • Patent number: 11377417
    Abstract: The present application relates to novel 3-phenylpropionic acid derivatives which carry a branched or cyclic alkyl substituent in the 3-position, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: July 5, 2022
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Michael Hahn, Thomas Lampe, Johannes-Peter Stasch, Karl-Heinz Schlemmer, Frank Wunder, Volkhart Min-Jian Li, Eva Maria Becker-Pelster, Friederike Stoll, Andreas Knorr, Elisabeth Woltering
  • Patent number: 11377434
    Abstract: The present disclosure relates to a method for preparing a compound of formula (1). In the compound of formula (1), n may be 0 to 5 and each of R1, R2, R3, and R4 may be independently selected from the group consisting of H, —O-Alkyl, halo, alkyl, —CN, or —NO3.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: July 5, 2022
    Assignee: HANGZHOU DUYI TECHNOLOGY CO. LTD.
    Inventors: Gaofeng Bian, Zengying Zheng
  • Patent number: 11377420
    Abstract: A highly effective synthetic route to produce donor-acceptor azetines through the highly enantioselective [3+1]-cycloaddition of silyl-protected enoldiazoacetates with aza-ylides using chiral copper(I) catalysis is provided. In one embodiment, the 2-azetidine cycloaddition products undergo generation of 3-azetidinones by reactions with nucleophiles that produce a broad spectrum of peptide products by the retro-Claisen reaction provided by facile strain with high efficacy and complete retention of enantiopurity. This ring opening reaction uncovers a new methodology for the attachment of chiral peptide units to a variety of amines and alcohols, and tolerates a broad scope of nucleophiles including naturally occurring amines, alcohols, amino acids, and other nitrogen based nucleophiles.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: July 5, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael Patrick Doyle, Kostiantyn Oleksandrovich Marichev
  • Patent number: 11377435
    Abstract: The present invention generally relates to carbon monoxide releasing compounds and compositions, and their use as carbon monoxide prodrugs. The compounds disclosed herein contain a cyclopentadienone moiety, a non-reactive dienophile, and an enzyme-cleavable tethering moiety connecting the cyclopentadienone moiety to the non-reactive dienophile. Cleavage of the enzyme-cleavable tethering moiety results in conversion of the non-reactive dienophile to a reactive dienophile.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: July 5, 2022
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Binghe Wang, Xingyue Ji
  • Patent number: 11370797
    Abstract: 7-Thio-substituted-3-nitro-1,2,4-triazolo [5,1-c]-1,2,4-triazin-4(1H)-one antiviral compounds, methods their preparation, and methods of their use in the treatment of positive-sense, single-stranded RNA virus infections different from the West Nile Fever virus infections are disclosed.
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: June 28, 2022
    Assignee: DORING INTERNATIONAL GMBH
    Inventors: Pavel Vladimirovich Sorokin, David Edmund Thorne
  • Patent number: 11369594
    Abstract: A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: June 28, 2022
    Assignee: Queen's University at Kingston
    Inventors: Rebecca Grange, John Allingham, Andrew Craig, P. Andrew Evans, Madhu Aeluri
  • Patent number: 11365263
    Abstract: The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula: F1-L1-T-L2-F2 where F1, L1, T, L2 and F2 are as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: June 21, 2022
    Assignee: PFIZER INC.
    Inventors: Andreas Maderna, Chakrapani Subramanyam, Lawrence N. Tumey, Zecheng Chen, Jeffrey M. Casavant
  • Patent number: 11358969
    Abstract: The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: June 14, 2022
    Assignee: IKENA ONCOLOGY, INC.
    Inventors: Alfredo C. Castro, Catherine A. Evans
  • Patent number: 11357861
    Abstract: Provided are a protein conjugate in which a physiologically active polypeptide is linked to a biocompatible material via a non-peptidyl polymer-coupled fatty acid derivative compound serving as a linker, exhibiting an increased duration of physiological activity compared to natural forms and a preparation method therefor. Since an increase in serum half-life of the physiologically active polypeptide of the protein conjugate, in which the biocompatible material, the non-peptidyl polymer-coupled fatty acid derivative compound, and the physiologically active polypeptide are linked, is proved, the protein conjugate may be widely used in the field of protein drugs.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: June 14, 2022
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Su Yeon Park, Ji Young Song, Eun Jung Kim, Jong Min Lee, Jong-Soo Lee, Dae Jin Kim
  • Patent number: 11352351
    Abstract: The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: June 7, 2022
    Assignee: ARVINAS OPERATIONS, INC.
    Inventors: Meizhong Jin, Andrew P. Crew, Hanqing Dong, Jing Wang, Xin Chen, Yimin Qian
  • Patent number: 11344530
    Abstract: An object of the present invention is to provide an excellent drug for preventing or treating spinocerebellar ataxia. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy, especially cerebellar atrophy, and is useful as an agent for preventing or treating spinocerebellar ataxia. Cerebellar atrophy observed in spinocerebellar ataxia can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: May 31, 2022
    Assignee: FUJIFILM Toyama Chemical Co., Ltd.
    Inventors: Hiroshi Kobayashi, Yoshihiko Matsumoto, Tomohiro Okuda